Inhibition of A549 cells by polybutylcyanoacrylate nanoparticles loaded with antisense oligodeoxynucleotide of hTERT mRNA

Yaoxue Xuebao

Volumn 41, Issue 5, 2006, Pages 446-451

  Zhang, Yan Yan ^a   Fu, Chun Jing ^a   Zhang, Zhen Zhong ^a  

^a ZHENGZHOU UNIVERSITY   (China)

Author keywords

A549 cells; Antisense oligodeoxynucleotide; Human telomerase reverse transcriptase; Polybutylcyanoacrylate nanoparticle

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; ENBUCRILATE; MESSENGER RNA; NANOPARTICLE; TELOMERASE; TERT PROTEIN, HUMAN;

ADENOCARCINOMA; ARTICLE; CELL CYCLE; CELL DEATH; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECT; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; HUMAN; LUNG TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ADENOCARCINOMA; CELL CYCLE; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; ENBUCRILATE; HUMANS; LUNG NEOPLASMS; NANOPARTICLES; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; RNA, MESSENGER; TELOMERASE; TRANSFECTION;

EID: 33745791730     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer [J]. Science, 1994, 266: 2011-2015.
2. Ito H, Kyo S, Kanaya T, et al. Expression of human telomerase subunites and correlation with telomerase activity in urothelial cancer [J]. Clin Cancer Res, 1998, 4: 1603-1608.
3. Zhang XN, Zhang Q, Wen H, et al. Preparation of albendazole polybutycyanocrylate nanoparticles and study on its pharmaceutical properties and tissue distribution [J]. Acta Pharm Sin, 2003, 38: 462-466.
4. Bennett WP, Hollstein MC, Hsu IC, et al. Mutational spectra and immunohistochemical analysis of p53 in human cancer [J]. Chest, 1992,101: 19S-20S.
5. Chavany C, Le Doan T, Couvreur P, et al. Polyalkylcyanoacrylate nanoparticles as polymeric carriers for antisense oligonucleotides [J]. Pharm Res, 1992, 9: 441-449.
6. Zimmer A. Antisense oligonucleotide delivery with polyhexylcyanoacrylate nanoparticles as carriers [J]. Methods, 1999, 18: 286-295.
7. Liu W, Zhang HL, Zhou TY, et al. Study on preparation of antisense oligodeoxynucleotides-loaded polybutylcyanoacrylate nanoparticles and its loading [J]. Chin Pharm J, 2005, 40: 1312-1315.
8. Yan P, Coindre JM, Benhattar J, et al. Telomerase activity and human telomerase reverse transcriptase mRNA expression in soft tissue tumors: correlation with grade, histology and proliferative activity [J]. Cancer Res, 1999, 59: 3166-3170.
9. Cho-Chung YS. Antisense DNAs as targeted therapeutics for cancer: no longer a dream [J]. Curr Opin Investig Drugs, 2002, 3: 934-939.
10. Lebeau J, Fouchet P, Ory K, et al. Down regulation of telomerase activity after progesterone treatment of human breast cancer cells: essential role of the cell cycle status [J]. Anticancer Res, 2002, 22: 2161-2166.
11. Kondo S, Tanaka Y, Kondo Y, et al. Antisense telomerase treatment: induction of two distinct pathways, apoptosis and differentiation [J]. FASEB J, 1998, 12: 801-811.